메뉴 건너뛰기




Volumn 41, Issue 6 PART 1, 2012, Pages 557-559

Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress;Thérapeutique anticoagulante: Savoir ne pas compromettre un progrès attendu

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BENZIMIDAZOLE DERIVATIVE; DABIGATRAN ETEXILATE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

EID: 84861977094     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.03.002     Document Type: Editorial
Times cited : (2)

References (17)
  • 1
    • 78149467425 scopus 로고    scopus 로고
    • Deux nouveaux anticoagulants disponibles en 2010 - dabigatran étexilate et rivaroxaban: progrès attendus - problèmes posés
    • Samama M.M., Conard J., Horellou M.H., Le Flem L., Guinet C., Depasse F. Deux nouveaux anticoagulants disponibles en 2010 - dabigatran étexilate et rivaroxaban: progrès attendus - problèmes posés. Ann Pharm Fra 2010, 68:359-369.
    • (2010) Ann Pharm Fra , vol.68 , pp. 359-369
    • Samama, M.M.1    Conard, J.2    Horellou, M.H.3    Le Flem, L.4    Guinet, C.5    Depasse, F.6
  • 2
    • 80052627217 scopus 로고    scopus 로고
    • Trois nouveaux anticoagulants disponibles en 2011: dabigatran étexilate, rivaroxaban et apixaban
    • Samama M.M., Gerotziafas G. Trois nouveaux anticoagulants disponibles en 2011: dabigatran étexilate, rivaroxaban et apixaban. Biotribune 2011, 38:10-15.
    • (2011) Biotribune , vol.38 , pp. 10-15
    • Samama, M.M.1    Gerotziafas, G.2
  • 6
    • 78649980897 scopus 로고    scopus 로고
    • Pharmacologic properties of the new oral anticoagulants: a clinician oriented review with a focus on perioperative management
    • Douketis J.D. Pharmacologic properties of the new oral anticoagulants: a clinician oriented review with a focus on perioperative management. Curr Pharm Des 2010, 16:3436-3441.
    • (2010) Curr Pharm Des , vol.16 , pp. 3436-3441
    • Douketis, J.D.1
  • 7
    • 80052395334 scopus 로고    scopus 로고
    • Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct: propositions du Groupe d'intérêt en hémostase périopératoire (GIHP) et du Groupe d'études sur lthom
    • Sie P., Samama C.M., Godier A., Rosencher N., Steib A., Llau J.V., et al. Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct: propositions du Groupe d'intérêt en hémostase périopératoire (GIHP) et du Groupe d'études sur l'hémostase et la thrombose (GEHT). Ann Fr Anesth Reanim 2001, 30:645-650.
    • (2001) Ann Fr Anesth Reanim , vol.30 , pp. 645-650
    • Sie, P.1    Samama, C.M.2    Godier, A.3    Rosencher, N.4    Steib, A.5    Llau, J.V.6
  • 8
    • 82555172355 scopus 로고    scopus 로고
    • Dabigatran: review of pharmacology and management of bleeding complications of this novel anticoagulant
    • Ganetsky M., Babu K.M., Salhanick S.D., Brown R.S., Boyer E.N. Dabigatran: review of pharmacology and management of bleeding complications of this novel anticoagulant. J Med Toxicol 2011, 7:281-287.
    • (2011) J Med Toxicol , vol.7 , pp. 281-287
    • Ganetsky, M.1    Babu, K.M.2    Salhanick, S.D.3    Brown, R.S.4    Boyer, E.N.5
  • 9
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
    • Van Ryn J., Stangier J., Haertter S., Liesenfeld K.H., Wienen W., Feuring M., et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2011, 103:1116-1127.
    • (2011) Thromb Haemost , vol.103 , pp. 1116-1127
    • Van Ryn, J.1    Stangier, J.2    Haertter, S.3    Liesenfeld, K.H.4    Wienen, W.5    Feuring, M.6
  • 10
    • 80053571188 scopus 로고    scopus 로고
    • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
    • Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
    • (2011) Circulation , vol.124 , pp. 1573-1579
    • Eerenberg, E.S.1    Kamphuisen, P.W.2    Sijpkens, M.K.3    Meijers, J.C.4    Buller, H.R.5    Levi, M.6
  • 12
    • 84861990990 scopus 로고    scopus 로고
    • Laboratory follow-up and clinical management of a patient case with severe bleeding complication on dabigatran for atrial fibrillation
    • Lassila R., Munsterhjelm E., Joutsi-Korhonen L., Armstrong E. Laboratory follow-up and clinical management of a patient case with severe bleeding complication on dabigatran for atrial fibrillation. J Thromb Haemost 2011, 9(Suppl. 2):840-841.
    • (2011) J Thromb Haemost , vol.9 , Issue.SUPPL. 2 , pp. 840-841
    • Lassila, R.1    Munsterhjelm, E.2    Joutsi-Korhonen, L.3    Armstrong, E.4
  • 13
    • 77953394559 scopus 로고    scopus 로고
    • Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. ASH Annual Meeting
    • Lu G., DeGuzman F.R., Lakhotia S., Hollenbach S.J., Phillips D.R., Sinha U. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. ASH Annual Meeting. Blood 2008, 112:983.
    • (2008) Blood , vol.112 , pp. 983
    • Lu, G.1    DeGuzman, F.R.2    Lakhotia, S.3    Hollenbach, S.J.4    Phillips, D.R.5    Sinha, U.6
  • 14
    • 84861975957 scopus 로고    scopus 로고
    • An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models? ISTH Kyoto
    • Van Ryn J., Litzenburger T., Waterman A., Canada K., Hauel N., Sarko C., et al. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models? ISTH Kyoto. J Thromb Haemost 2011, 9(Suppl. 2):110.
    • (2011) J Thromb Haemost , vol.9 , Issue.SUPPL. 2 , pp. 110
    • Van Ryn, J.1    Litzenburger, T.2    Waterman, A.3    Canada, K.4    Hauel, N.5    Sarko, C.6
  • 15
    • 84861990943 scopus 로고    scopus 로고
    • Carnet-conseils. Vous et votre nouveau traitement anticoagulant site
    • Carnet-conseils. Vous et votre nouveau traitement anticoagulant site http://www.gita-thrombose.org/.
  • 16
    • 80052145294 scopus 로고    scopus 로고
    • A patient's guide to taking dabigatran etexilate
    • Spinler S.A., Willey V.J. A patient's guide to taking dabigatran etexilate. Circulation 2011, 124:209-211.
    • (2011) Circulation , vol.124 , pp. 209-211
    • Spinler, S.A.1    Willey, V.J.2
  • 17
    • 84858415439 scopus 로고    scopus 로고
    • Important data after drug approval: comment on dabigatran association with higher risk of acute coronary events
    • Redberg R.F. Important data after drug approval: comment on dabigatran association with higher risk of acute coronary events. Arch Intern Med 2012, 10.1001/archinternmed.2011.2169.
    • (2012) Arch Intern Med
    • Redberg, R.F.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.